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Abstract
Background: Postoperative atrial fibrillation (POAF) is the most common complication after coronary artery bypass
grafting (CABG). The preventive effect of magnesium on POAF is not well known. This meta-analysis was
undertaken to assess the efficacy of intravenous magnesium on the prevention of POAF after CABG.
Methods: Eligible studies were identified from electronic databases (Medline, Embase, and the Cochrane Library).
The primary outcome measure was the incidence of POAF. The meta-analysis was performed with the fixed-effect
model or random-effect model according to heterogeneity.
Results: Seven double-blind, placebo-controlled, randomized clinical trials met the inclusion criteria including 1,028
participants. The pooled results showed that intravenous magnesium reduced the incidence of POAF by 36% (RR
0.64; 95% confidence interval (CI) 0.50-0.83; P = 0.001; with no heterogeneity between trials (heterogeneity P = 0.8,
I
2 = 0%)).
Conclusions: This meta-analysis indicates that intravenous magnesium significantly reduces the incidence of POAF
after CABG. This finding encourages the use of intravenous magnesium as an alternative to prevent POAF after
CABG. But more high quality randomized clinical trials are still need to confirm the safety.
Introduction
Postoperative atrial fibrillation (POAF) is the most com-
mon complication encountered following coronary artery
bypass grafting (CABG). It generally occurs between 24
and 96 h postoperatively, with a peak incidence on the
second postoperative day [1-3]. With continuous electro-
cardiographic monitoring, the incidence of atrial fibrilla-
tion after CABG reported in previous studies varies from
10% to 50% [1,2,4], and this incidence has not decreased
despite improvements in anesthetic and surgical techni-
ques [5,6]. Furthermore, atrial fibrillation potentially
leads to complications, including stroke [7-9], extended
duration of hospitalization [7-10], and increasing costs
[1,9,10].
The etiology of atrial fibrillation after CABG is unclear.
The cause may be multifactorial, such as advanced age,
previous history of atrial fibrillation, and low blood mag-
nesium concentrations [11-13]. There are many pharma-
cologic agents to prevent POAF, but none of them are
effective for all patients and are free of complications [14].
Particularly, magnesium seems to be with great promise to
prevent POAF following CABG.
A previous meta-analysis of magnesium for prevention
of atrial fibrillation after CABG including eight rando-
mized controlled trials was published in 2005 [15]. The
analysis showed that intravenous magnesium is associated
with a significant reduction in the incidence of atrial fibril-
lation after CABG, with a relative risk of 0.64 (95% confi-
dence interval (CI) 0.47-0.87). But this meta-analysis
included some clinical studies which had a modest sample
size. Moreover, some of these included studies are of low
quality. Recently, an increasing number of studies on the
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POAF have been published. These studies have contrasted
in these randomized controlled trials. Therefore, we per-
formed an updated meta-analysis only based on double-
blind, placebo-controlled, randomized clinical trials to
re-examine the effects of intravenous magnesium on the
prevention of POAF after CABG.
Materials and methods
Search strategy and selection criteria
Two investigators (WJG and ZJW) independently searched
the literatures collected in Medline, Embase, and the
Cochrane Library up to August 1, 2011. Search terms
included: magnesium, fibrillation. The searches were lim-
ited to English publications in humans. We screened the
reference lists of included studies and related publications.
The results were then hand searched for eligible trials. We
did not include abstracts or meeting proceedings. This
search strategy was performed iteratively until no new
potential citations could be found on review of the refer-
ence lists of retrieved articles.
We included full-text publications when the following
inclusion criteria were met: adult patients undergoing
CABG only; randomized allocation to magnesium group
or control group (only placebo); double-blind, placebo-
controlled, randomized clinical trial; and providing avail-
able data on the incidence of POAF. Exclusion criteria
included: (a) unavailable duration of follow-up; and (b)
some patients reported with pre-existing atrial fibrillation.
The trials with small sample size of (n <1 0 )w e r ea l s o
excluded to avoid selection bias.
Data extraction and quality assessment
Two investigators (WJG and ZJW) independently
extracted the following information from each study: the
first author’s name, year of publication, country of origin,
participants’ characteristics, study design (randomized),
type of controls (placebo), data collection (prospective or
not), sampling method (consecutive or not), type of blind-
ing (double blind), duration of follow-up, regimen of mag-
nesium administration, the timing of magnesium infusion
was initiated (preoperative, intraoperative, or postopera-
tive), number, mean age and percentage of males in each
trial, total number of individuals, and the incidence of
POAF in each group. When the same population was
reported in several publications, we retained only the most
informative article or completed study to avoid duplication
of information. Any disagreements were resolved through
discussion and consensus.
The methodological quality of the studies included in
the meta-analysis was scored using validated Jadad 5-
point scale. The scale consists of three items describing
randomization (0-2 points), double-blind (0-2 points),
and drop-outs and withdrawals (0-1 points) in the report
of a randomized controlled trial. One point was given
when one quality criterion was met. The quality scale
ranges from 0 to 5 points. Higher scores indicate better
reporting. The studies are said to be of low quality if the
Jadad score is ≤ 2a n dh i g hq u a l i t yi ft h es c o r ei s≥ 3
[16,17].
Statistical analysis
Data were analyzed using Stata version 11 (Stata Corpora-
tion, College Station, TX, USA). A statistical test with a
P value less than 0.05 was considered significant. The inci-
dence of POAF was treated as dichotomous variables and
was expressed as risk ratio (RR) with 95% CI for each
study. Pooled estimates of efficacy were calculated using
the Man-tel-Haenszel fixed-effects model [18]. But if there
was heterogeneity, the following methods were used to
deal with it: (a) subgroup analysis; (b) sensitivity analysis
performed by excluding trials which potentially biased the
results. If heterogeneity still potentially existed, the DerSi-
monian and Lair random-effects model was used. A test
for heterogeneity, defined as variation among the results
of individual trials for a given treatment beyond that
expected from chance, was used to assess whether the
magnitude of a given preventive effect varied between the
trials. We assessed heterogeneity with I
2, which describes
the percentage of total variation across studies due to het-
erogeneity rather than chance. I
2 can be calculated as: I
2 =
100% × (Q-df)/Q(Q = Cochrane’s heterogeneity statistics,
df = degrees of freedom). Negative values of I
2 equaled
zero, so that I
2 ranged between 0% (that is no observed
heterogeneity) and 100%. High values would show increas-
ing heterogeneity. Studies with an I
2 statistic of 25% to
50% are considered to have low heterogeneity, those with
an I
2 statistic of 50% to 75% are considered to have mod-
erate heterogeneity, and those with an I
2 statistic of > 75%
are considered to have a high degree of heterogeneity [19].
The presence of publication bias was evaluated by using
the Egger test [20].
Results
Seven double-blind, placebo-controlled, randomized clini-
cal trials consisting of 1,028 individuals were included in
this study. Four of the eight randomized controlled trials
published by Alghamdi et al. [15] were also included and
the remaining four trials were excluded because they were
non-double-blind. Three eligible studies were published
after 2003. The flow of identified studies through the
selection process is shown in Figure 1.
Description of eligible trials
The efficacy of intravenous magnesium with placebo on
the prevention of POAF was compared in these trials.
The baseline characteristics of included studies are
shown in Table 1 and the design characteristics are
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in the USA, one in UK, one in Turkey, one in Switzer-
land, one in Iran, and one in Pakistan. The number of
participants ranged from 50 to 345. All trials included
both men and women. The total dosage of intravenous
magnesium in the intervention groups ranged from 8 to
100 mmol (one trial [21] was not available). The follow-
up time ranged from 1 to 5 days (one trial [11] was fol-
lowed up until atrial fibrillation developed and needed
therapeutic intervention). All trials reported periopera-
tive prophylactic use of intravenous magnesium: one
trial [21] was initiated during the preoperative period,
two trials [11,22] during the intraoperative period, and
four trials [23-26] during the postoperative period.
Quality assessment of the trials
The trials included in this meta-analysis appeared to have
been reasonably designed and conducted. All studies had
a statement regarding randomization and double-blind.
Four trials described the methods of randomization. Four
trials reported the withdrawals or dropouts. All trials
described the main outcome, and no missing data
seemed to influence the results. The quality of the
included studies was assessed by the Jadad score. The
median Jadad score of the studies included was 4 (range
from 3 to 5, Table 2).
The incidence of POAF
Analysis of pooled prevalence of preoperative patient
group characteristics revealed that no differences were
observed for history of coexistence of basic diseases (for
example diabetes mellitus, hypertension) and routine
prophylactic therapies (for example b-blockers; Table 3).
Pooling all seven trials, of 511 patients in the pooled
intervention (intravenous magnesium) group, 76 devel-
oped POAF, compared to 116 out of 517 patients in the
pooled control group. The pooled analysis showed that
intravenous magnesium significantly reduced the inci-
dence of POAF by 36% (RR 0.64; 95% CI 0.50-0.83; P =
0.001; Figure 2), with no heterogeneity between trials (het-
erogeneity P = 0.8; I
2 = 0%).
Subgroup analyses were done according to data collec-
tion, sampling method and the duration of follow-up.
Pooled results of five prospective trials [11,21,23,24,26]
showed intravenous magnesium significantly reduced the
incidence of POAF by 37% (RR 0.63, 95% CI 0.48-0.83;
P = 0.001; heterogeneity P =0 . 7 ,I
2 = 0%). Pooled results
of four consecutive patients trials [11,23,24,26] showed
that intravenous magnesium significantly reduced the inci-
dence of POAF by 44% (RR 0.56, 95% CI 0.37-0.83; P =
0.005; heterogeneity P =0 . 7 ,I
2 =0 % ) .E x c l u s i o no ft h e
Hamid et al. trial [22] in which the duration of follow-up
is just 1 day yielded similar results (RR 0.66, 95% CI 0.51-
0.85; P = 0.002; heterogeneity P = 0.8; I
2 = 0%). The sum-
mary of subgroup analyses results is shown in Table 4.
Publication bias
Assessment of publication bias using Egger’st e s t
showed that moderate publication bias existed among
the included trials (Egger’s test: P = 0.045; Figure 3).
Discussion
This is a further meta-analysis to evaluate the relation-
ship between intravenous magnesium and POAF. All
trials included in this analysis are double-blind, placebo-
controlled, randomized clinical trials. The data can give
Figure 1 Process of study selection of double-blind, placebo-controlled, randomized trials.
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Page 3 of 8Table 1 Characteristics of studies included in the meta-analysis
Author n Regimen of magnesium administration
a Control
regimen
(route)
Total dose
Mg
2+ (mmol)
Magnesium Controls POAF
Age (years),
(male, %)
n Age (years),
(male, %)
n Magnesium
(%) Controls
(%)
Fanning et
al.[23]
99 168 mEq over the first 4 postoperative days 5% dextrose
solution (IV)
84 mmol 59 (43-75) 49
(71.4)
62 (42-79) 50
(78)
7/49
(14.3)
14/50
(28)
Colquhoun
et al.[24]
130 50 mmol during the first 48 h after surgery 5% dextrose
solution (IV)
50 mmol 57.1 ± 8.4 66
(83.3)
58.7 ± 7.9 64
(79.7)
11/66
(16.7)
15/64
(23.4)
Nurozler et
al.[26]
50 100 mEq on the first operative day and 25 mEq per day from second to fifth
days
Placebo (IV) 100 mmol 56.3 ± 1.6 25
(92)
53.6 ± 2.0 25
(92)
1/25
(4)
5/25
(20)
Treggiari-
Venzi et al.
[25]
98 4 g per 24 h continuous infusion for 72 h starting within 1 h of arrival in the ICU 0.9% NaCl
solution (IV)
48 mmol 65 (46-81) 47
(89.4)
65 (37-88) 51
(84.3)
11/47
(23)
14/51
(27)
Hazelrigg et
al.[21]
202 80 mg/kg (ideal body weight) before cardiopulmonary bypass (CPB), 8 mg/kg/h
(ideal body weight) intravenous (IV) infusion continued for 48 h
5% dextrose
solution (IV)
NA 62.1 ± 9.5 105
(74)
63.7 ± 11.1 97
(68)
32/105
(30.5)
41/97
(42.3)
Najafi et al.
[11]
345 2 g after induction of anesthesia until the start of cardiopulmonary bypass (CPB)
and 8 g after CABG until 24 h after surgery
Placebo (IV) 40 mmol 59.1 (9.1) 166
(75.9)
59.7 (9.9) 179
(76.5)
12/166
(7.2)
22/179
(12.3)
Hamid et al.
[22]
104 2 g after intubation 0.9% NaCl
solution (IV)
8 mmol 58.3 ± 7.6 53
(98)
56.3 ± 8.9 51
(86)
2/53
(3.77)
5/51
(9.8)
aTo convert units of g and mEq to mmol, the following conversions were used; 1 g = 4 mmol = 8 mEq for MgSO4.
CABG, coronary artery bypass grafting; CPB, cardiopulmonary bypass; ICU, intensive care unit;IV, intravenous; n, number of participants; NA, data not available; POAF, postoperative atrial fibrillation;
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8greater power to assess the efficacy of intravenous mag-
nesium on the prevention of atrial fibrillation after
CABG. We combined the effect sizes of all seven
included trials that used intravenous magnesium for
preventing POAF through a fixed-effects model and
found that intravenous magnesium significantly reduced
the incidence of POAF by 36%. A meta-analysis of data
collected before December 2003 [15] found a cumula-
tive RR of 0.64 (95% CI: 0.47-0.87) for the randomized
controlled trials. Our findings are consistent with this
previous meta-analysis.
This meta-analysis shows diversity in the dosing, timing
and duration of magnesium administration. The diversity
accounts for the inconsistency in the reported outcomes
of the included trials as listed in Table 1. In three
[23,24,26] of the prospectively controlled clinical trials
[11,21,23,24,26], intravenous magnesium significantly
reduced the incidence of POAF after CABG. In three
trials, magnesium was dosed for at least 2 consecutive
days postoperatively. Given that the onset of POAF follow-
ing CABG generally occurs between 24 and 96 h post-
operatively, with a peak incidence on the second
postoperative day and that it is often associated with hypo-
magnesaemia, intravenous magnesium supplementation
during this period may play a key role in the suppression
of POAF.
Demographic bias owing to generating the sequence of
randomization inadequately may be another reason for
the discordance in the reported results of magnesium
prophylaxis. The biased variable, if it happens to be a
powerful predictor of POAF, would apparently have a
strong influence on the outcome of the study. For
example, one trial [22] showed that prophylactic magne-
sium supplementation does not significantly reduce the
incidence of POAF, patients in the magnesium group had
a higher ratio of male gender (98% versus 86%, P =0 . 0 2 ) .
This characteristic, male gender has been consistently a
risk factor for the development of POAF.
Up to now, various preventive methods including phar-
macologic and non-pharmacologic interventions have
been proposed in the preventive strategy of POAF.
Current evidences from meta-analyses [27-29] suggest
that beta-blockers are effective and safe for most patients
and advise that clinicians should not discontinue beta-
blockers before cardiac surgery, unless contraindicated.
Amiodarone can be safely added in patients at high risk
for atrial fibrillation. In a recent meta-analysis, however,
Patel et al. [30] found that amiodarone increases the risk
of bradycardia and hypotension, particularly when admi-
nistered intravenously. Meta-analyses of the clinical trials
[8,29,31] investigating the effect of prophylactic pacing
have consistently suggested that single- or dual-site atrial
pacing significantly reduces the incidence of POAF; how-
ever, it is limited in practical use because of its complex-
ity. Furthermore, there are some other pharmaceuticals
such as statins [32,33], N-3 polyunsaturated fatty acids
[34], and anti-inflammatory agents [35,36] being used to
prevent POAF following CABG. However, the number of
enrolled patients in these trails was small, and the phar-
maceutical doses and administration times varied widely
among studies. Thus, further studies are still necessary
before confirmed conclusion. In a prospective, rando-
mized, double-blind, placebo-controlled study, Cagli
et al. [37] have concluded that low-dose amiodarone and
Table 2 Included studies design characteristics
Author Publication
year
Country Study design Data
collection
Sampling
method
Blind Follow-up
(days)
Jadad
score
Fanning et al.[23] 1991 USA Randomized, placebo-controlled Prospective Consecutive DB 4 4
Colquhoun et al.[24] 1993 UK Randomized, placebo-controlled Prospective Consecutive DB 4 4
Nurozler et al.[26] 1996 Turkey Randomized, placebo-controlled Prospective Consecutive DB 5 3
Treggiari-Venzi et al.[25] 2000 Switzerland Randomized, placebo-controlled NA NA DB 3 5
Hazelrigg et al.[21] 2004 USA Randomized, placebo-controlled Prospective NA DB 5 4
Najafi et al.[11] 2007 Iran Randomized, placebo-controlled Prospective Consecutive DB Until AF
developed and
needed
therapeutic
intervention
4
Hamid et al.[22] 2008 Pakistan Randomized, placebo-controlled NA NA DB 1 4
AF, atrial fibrillation; DB, double-blind; NA, data not available
Table 3 Perioperative variables of the patients
Variable Magnesium (% (n)) Control (% (n)) x
2 value P value Total prevalence (% (n))
Diabetes mellitus [11,24-26] 22.4 (68/304) 21.9 (70/319) 0.016 0.9 22.2 (138/623)
Hypertension [24-26] 31.2 (43/138) 27.1 (38/140) 0.543 0.5 29.1 (81/278)
b-blocker [21-25] 45.6 (146/320) 48.6 (152/313) 0.548 0.5 47.1 (298/633)
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Table 4 The summary of subgroup analyses results
Subgroup analysis Studies (n) Participants (n) RR (95% CI) I
2(%) P heterogeneity P value
Prospective 5 826 0.63 (0.48-0.83) 0.00 0.7 0.001
Consecutive 4 624 0.56 (0.37-0.83) 0.00 0.7 0.005
Follow-up 6 924 0.66 (0.51-0.85) 0.00 0.8 0.002
CI, confidence interval; n, number of studies; RR, risk ratio
Figure 3 Tests for publication bias for RR of the incidence of POAF.
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Page 6 of 8magnesium combination is an effective, simple, well-tol-
erated, and possibly cost-effective regimen to prevent
atrial fibrillation after CABG for high-risk patients. Per-
haps appropriate combinations of these pharmacologic
and non-pharmacologic interventions might be of benefit
for further reducing POAF. In this meta-analysis, the
patient population enrolled was quite homogeneous in its
presentation. The studies included are of high quality,
and all seven studies are double-blind, placebo-
controlled, randomized trials having a Jadad score of ≥ 3.
We combined all the studies using a fixed-effects mode
and tested heterogeneity between trials with I
2 (0.0%) and
with P value (0.8), indicating no heterogeneity.
Several potential limitations of this meta-analysis merit
consideration. First, we accept that our meta-analysis
included some clinical studies which had a modest sample
size. Although we aimed to retrieve additional data from
investigators, it was inevitable that some missing and
unpublished data may still exist. Second, the exclusion of
non-English-language studies and studies with fewer than
10 patients may lead to bias in effect size. In addition, fol-
low-up time varied among included studies, and different
total dose of intravenous magnesium was adopted in these
studies. The discrepancy may explain clinical heterogene-
ity among studies, although no statistical heterogeneity is
found.
Conclusion
This meta-analysis of all seven double-blind, placebo-con-
trolled, randomized clinical trials shows that intravenous
magnesium significantly reduced the incidence of POAF
after CABG by 36%. Pooled analysis of five prospective
trials shows intravenous magnesium significantly reduced
the incidence of POAF by 37%, and pooled analysis of four
consecutive patient trials shows that intravenous magne-
sium significantly reduced the incidence of POAF by 44%.
This finding encourages the use of intravenous magne-
sium as an alternative to prevent POAF after CABG but
more high quality randomized clinical trials are still need
to confirm the safety.
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